Is ajovy for migraines?

Is Ajovy approved to treat migraines?

Ajovy is approved by the FDA to prevent migraine headaches in adults. It works by targeting calcitonin gene-related peptide (CGRP), a protein that plays a key role in triggering migraines. The approval came in September 2018.

What does the monthly injection look like?

The monthly version uses 225 mg delivered subcutaneously once every month. The higher-dose option uses 675 mg delivered three consecutive times at the beginning of each quarter. Both options show similar wirkung in reducing monthly migraine days.

How does Ajovy compare with other CGRP drugs?

Other CGRP monoclonal antibodies include Emgality and Aimovig. Ajovy offers a flexible dosing schedule that allows users to choose between monthly and quarterly injections. Some patients prefer this flexibility over the monthly-only rules for other drugs. The three-monthly option also saves time and reduces injection burden.

When does Ajovy’s patent expire?

Ajovy’s composition-of-matter patent expires in 2033. The company has filed several secondary patents covering formulation and dosing methods. Secondary patents can extend exclusivity beyond the core patent date. DrugPatentWatch.com tracks these dates and updates them regularly.